Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group

Raymond Y. Huang, Wenya Linda Bi, Michael Weller, Thomas Kaley, Jaishri Blakeley, Ian Dunn, Evanthia Galanis, Matthias Preusser, Michael McDermott, Leland Rogers, Jeffrey Raizer, David Schiff, Riccardo Soffietti, Jörg Christian Tonn, Michael Vogelbaum, Damien Weber, David A. Reardon, Patrick Y. Wen

Research output: Contribution to journalArticle

Abstract

No standard criteria exist for assessing response and progression in clinical trials involving patients with meningioma, and there is no consensus on the optimal endpoints for trials currently under way. As a result, there is substantial variation in the design and response criteria of meningioma trials, making comparison between trials difficult. In addition, future trials should be designed with accepted standardized endpoints. The Response Assessment in Neuro-Oncology Meningioma Working Group is an international effort to develop standardized radiologic criteria for treatment response for meningioma clinical trials. In this proposal, we present the recommendations for response criteria and endpoints for clinical trials involving patients with meningiomas.

Original languageEnglish (US)
Pages (from-to)26-36
Number of pages11
JournalNeuro-Oncology
Volume21
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Meningioma
Clinical Trials

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Proposed response assessment and endpoints for meningioma clinical trials : report from the Response Assessment in Neuro-Oncology Working Group. / Huang, Raymond Y.; Bi, Wenya Linda; Weller, Michael; Kaley, Thomas; Blakeley, Jaishri; Dunn, Ian; Galanis, Evanthia; Preusser, Matthias; McDermott, Michael; Rogers, Leland; Raizer, Jeffrey; Schiff, David; Soffietti, Riccardo; Tonn, Jörg Christian; Vogelbaum, Michael; Weber, Damien; Reardon, David A.; Wen, Patrick Y.

In: Neuro-Oncology, Vol. 21, No. 1, 01.01.2019, p. 26-36.

Research output: Contribution to journalArticle

Huang, RY, Bi, WL, Weller, M, Kaley, T, Blakeley, J, Dunn, I, Galanis, E, Preusser, M, McDermott, M, Rogers, L, Raizer, J, Schiff, D, Soffietti, R, Tonn, JC, Vogelbaum, M, Weber, D, Reardon, DA & Wen, PY 2019, 'Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group', Neuro-Oncology, vol. 21, no. 1, pp. 26-36. https://doi.org/10.1093/neuonc/noy137
Huang, Raymond Y. ; Bi, Wenya Linda ; Weller, Michael ; Kaley, Thomas ; Blakeley, Jaishri ; Dunn, Ian ; Galanis, Evanthia ; Preusser, Matthias ; McDermott, Michael ; Rogers, Leland ; Raizer, Jeffrey ; Schiff, David ; Soffietti, Riccardo ; Tonn, Jörg Christian ; Vogelbaum, Michael ; Weber, Damien ; Reardon, David A. ; Wen, Patrick Y. / Proposed response assessment and endpoints for meningioma clinical trials : report from the Response Assessment in Neuro-Oncology Working Group. In: Neuro-Oncology. 2019 ; Vol. 21, No. 1. pp. 26-36.
@article{de3b52308e8143d3b6162d384a6e4341,
title = "Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group",
abstract = "No standard criteria exist for assessing response and progression in clinical trials involving patients with meningioma, and there is no consensus on the optimal endpoints for trials currently under way. As a result, there is substantial variation in the design and response criteria of meningioma trials, making comparison between trials difficult. In addition, future trials should be designed with accepted standardized endpoints. The Response Assessment in Neuro-Oncology Meningioma Working Group is an international effort to develop standardized radiologic criteria for treatment response for meningioma clinical trials. In this proposal, we present the recommendations for response criteria and endpoints for clinical trials involving patients with meningiomas.",
author = "Huang, {Raymond Y.} and Bi, {Wenya Linda} and Michael Weller and Thomas Kaley and Jaishri Blakeley and Ian Dunn and Evanthia Galanis and Matthias Preusser and Michael McDermott and Leland Rogers and Jeffrey Raizer and David Schiff and Riccardo Soffietti and Tonn, {J{\"o}rg Christian} and Michael Vogelbaum and Damien Weber and Reardon, {David A.} and Wen, {Patrick Y.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1093/neuonc/noy137",
language = "English (US)",
volume = "21",
pages = "26--36",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Proposed response assessment and endpoints for meningioma clinical trials

T2 - report from the Response Assessment in Neuro-Oncology Working Group

AU - Huang, Raymond Y.

AU - Bi, Wenya Linda

AU - Weller, Michael

AU - Kaley, Thomas

AU - Blakeley, Jaishri

AU - Dunn, Ian

AU - Galanis, Evanthia

AU - Preusser, Matthias

AU - McDermott, Michael

AU - Rogers, Leland

AU - Raizer, Jeffrey

AU - Schiff, David

AU - Soffietti, Riccardo

AU - Tonn, Jörg Christian

AU - Vogelbaum, Michael

AU - Weber, Damien

AU - Reardon, David A.

AU - Wen, Patrick Y.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - No standard criteria exist for assessing response and progression in clinical trials involving patients with meningioma, and there is no consensus on the optimal endpoints for trials currently under way. As a result, there is substantial variation in the design and response criteria of meningioma trials, making comparison between trials difficult. In addition, future trials should be designed with accepted standardized endpoints. The Response Assessment in Neuro-Oncology Meningioma Working Group is an international effort to develop standardized radiologic criteria for treatment response for meningioma clinical trials. In this proposal, we present the recommendations for response criteria and endpoints for clinical trials involving patients with meningiomas.

AB - No standard criteria exist for assessing response and progression in clinical trials involving patients with meningioma, and there is no consensus on the optimal endpoints for trials currently under way. As a result, there is substantial variation in the design and response criteria of meningioma trials, making comparison between trials difficult. In addition, future trials should be designed with accepted standardized endpoints. The Response Assessment in Neuro-Oncology Meningioma Working Group is an international effort to develop standardized radiologic criteria for treatment response for meningioma clinical trials. In this proposal, we present the recommendations for response criteria and endpoints for clinical trials involving patients with meningiomas.

UR - http://www.scopus.com/inward/record.url?scp=85059247838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059247838&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noy137

DO - 10.1093/neuonc/noy137

M3 - Article

C2 - 30137421

AN - SCOPUS:85059247838

VL - 21

SP - 26

EP - 36

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 1

ER -